MARKET

PACB

PACB

PacBio
NASDAQ

Real-time Quotes | Nasdaq Last Sale

29.90
+0.63
+2.15%
Opening 11:21 03/08 EST
OPEN
30.49
PREV CLOSE
29.27
HIGH
31.37
LOW
28.33
VOLUME
1.56M
TURNOVER
--
52 WEEK HIGH
53.69
52 WEEK LOW
2.200
MARKET CAP
5.77B
P/E (TTM)
611.45
1D
5D
1M
3M
1Y
5Y
Next-Generation Sequencing Market Size 2021 With Top Countries Data, Opportunities by Regions, Emerging Downstream Market Analysis, Technological and Market Developments, Revenue, Prominent Players, Tendencies and Forecast to 2026
The Express Wire · 2d ago
GSX Techedu, Norwegian Cruise Line Holdings leads the premarket losers' pack
Evofem Biosciences EVFM -25% on Q4 earnings release.Super League Gaming (SLGG) -19%.GSX Techedu GSX -15% on Q4 earnings release.T2 Biosystems TTOO -10% on Q4 earnings release.Senseonics Holdings SENS -9% on Q4 earnings release.Aerpio Pharmaceuticals ARPO -...
Seekingalpha · 3d ago
Global Next-generation Sequencing Market Report 2020-2025 - Enhancing Regulatory Framework for Next-generation Sequencing Based Tests for Diagnostics Driving Growth
Dublin, March 05, Mar 05, 2021 (GLOBE NEWSWIRE via COMTEX) -- Dublin, March 05, 2021 (GLOBE NEWSWIRE) -- The "Global Next-generation Sequencing Market, by...
GlobeNewswire · 3d ago
NGS-based RNA-Seq Market Is Projected To Grow At A Moderate CAGR During The Period 2020-2025
AmericaNewsHour · 3d ago
Global Next-Generation Sequencing (NGS) Market | Analysis Industry Price 2020, Trends, Growth, Size, and Forecast To 2027
Comserve · 3d ago
Global Next Generation Sequencers Market Growth 2021-2026 With Top Countries Data Analysis by Industry Trends, Size, Share, Company Overview, Growth, Development and Forecast | With Covid 19 Analysis
Mar 04, 2021 (The Expresswire) -- “Next Generation Sequencers Market” Report (2021-2026) offers a learned and top to bottom investigation on the current...
The Express Wire · 3d ago
Worldwide Neurodiagnostics Industry to 2025 - Increasing Application in Clinical Trials Presents Opportunities
Dublin, March 04, Mar 04, 2021 (GLOBE NEWSWIRE via COMTEX) -- Dublin, March 04, 2021 (GLOBE NEWSWIRE) -- The "Global Neurodiagnostics market (2020-2025) by...
GlobeNewswire · 4d ago
Pacific Biosciences Grants Equity Incentive Award to New Employee
MENLO PARK, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) (“Pacific Biosciences” or the “Company”), a leading provider of high-quality sequencing of genomes, transcriptomes, and epigenomes, today announce...
GlobeNewswire · 5d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PACB. Analyze the recent business situations of PacBio through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PACB stock price target is 51.50 with a high estimate of 62.00 and a low estimate of 45.00.
EPS
Institutional Holdings
Institutions: 332
Institutional Holdings: 182.70M
% Owned: 94.61%
Shares Outstanding: 193.10M
TypeInstitutionsShares
Increased
67
22.70M
New
103
18.65M
Decreased
53
18.61M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
+0.34%
Healthcare Equipment & Supplies
+0.82%
Key Executives
Chairman/Independent Director
John Milligan
President/Chief Executive Officer/Director
Christian Henry
Chief Financial Officer/Chief Accounting Officer
Susan Kim
Lead Director/Independent Director
Bill Ericson
Chief Operating Officer
Mark Van Oene
Chief Accounting Officer/Vice President
Eric Schaefer
Vice President
Chris Seipert
Vice President
Denis Zaccarin
Other
Peter Fromen
Director
Michael Hunkapiller
Director
Kathy Ordonez
Independent Director
David Botstein
Independent Director
William Ericson
Independent Director
Randall Livingston
Independent Director
Marshall Mohr
Independent Director
Lucy Shapiro
No Data
  • All
  • Financials
  • Insiders
More
About PACB
Pacific Biosciences of California, Inc. designs, develops and manufactures sequencing systems to help scientists resolve genetically complex problems. The Company is engaged in the development, manufacturing and marketing of an integrated platform for genetic analysis. Its Single Molecule, Real-Time (SMRT) technology enables single molecule, real-time detection of biological processes. It offers The SMRT Cell, Phospholinked nucleotides and The PacBio RS II and Sequel instruments. Its SMRT technology enables the observation of deoxyribonucleic acid (DNA) synthesis as it occurs in real-time by harnessing the natural process of DNA replication, which is actuated by the DNA polymerase. Its phospholinked nucleotides have a fluorescent dye attached to the phosphate chain of the nucleotide rather than to the base. The PacBio RS II and Sequel instruments include optics, automated liquid handling, a touchscreen control interface and computational hardware and software.

Webull offers kinds of Pacific Biosciences of California Inc stock information, including NASDAQ:PACB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PACB stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PACB stock methods without spending real money on the virtual paper trading platform.